392 related articles for article (PubMed ID: 24752673)
1. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250.
Muselaers CH; Rijpkema M; Bos DL; Langenhuijsen JF; Oyen WJ; Mulders PF; Oosterwijk E; Boerman OC
J Urol; 2015 Aug; 194(2):532-8. PubMed ID: 25686542
[TBL] [Abstract][Full Text] [Related]
3. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
[TBL] [Abstract][Full Text] [Related]
4. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
[TBL] [Abstract][Full Text] [Related]
5. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Hekman MC; Rijpkema M; Muselaers CH; Oosterwijk E; Hulsbergen-Van de Kaa CA; Boerman OC; Oyen WJ; Langenhuijsen JF; Mulders PF
Theranostics; 2018; 8(8):2161-2170. PubMed ID: 29721070
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
[TBL] [Abstract][Full Text] [Related]
8. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
[TBL] [Abstract][Full Text] [Related]
9. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
10. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
11. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
[TBL] [Abstract][Full Text] [Related]
12. Preclinical validation of
Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
[TBL] [Abstract][Full Text] [Related]
14. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
van Brussel AS; Adams A; Vermeulen JF; Oliveira S; van der Wall E; Mali WP; van Diest PJ; van Bergen En Henegouwen PM
Breast Cancer Res Treat; 2013 Jul; 140(2):263-72. PubMed ID: 23860929
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
[TBL] [Abstract][Full Text] [Related]
17. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
19. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
Yang X; Minn I; Rowe SP; Banerjee SR; Gorin MA; Brummet M; Lee HS; Koo SM; Sysa-Shah P; Mease RC; Nimmagadda S; Allaf ME; Pomper MG
Oncotarget; 2015 Oct; 6(32):33733-42. PubMed ID: 26418876
[TBL] [Abstract][Full Text] [Related]
20. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
